These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28258040)

  • 21. Angiogenesis: an improved in vitro biological system and automated image-based workflow to aid identification and characterization of angiogenesis and angiogenic modulators.
    Santos AF; Zaltsman AB; Martin RC; Kuzmin A; Alexandrov Y; Roquemore EP; Jessop RA; van Erck MG; Verheijen JH
    Assay Drug Dev Technol; 2008 Oct; 6(5):693-710. PubMed ID: 19035850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Marine bromophenol bis (2,3-dibromo-4,5-dihydroxy-phenyl)-methane inhibits the proliferation, migration, and invasion of hepatocellular carcinoma cells via modulating β1-integrin/FAK signaling.
    Wu N; Luo J; Jiang B; Wang L; Wang S; Wang C; Fu C; Li J; Shi D
    Mar Drugs; 2015 Feb; 13(2):1010-25. PubMed ID: 25689564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
    Tandle A; Libutti SK
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiogenesis and antiangiogenic therapy in hematologic malignancies.
    Dong X; Han ZC; Yang R
    Crit Rev Oncol Hematol; 2007 May; 62(2):105-18. PubMed ID: 17188504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Marine natural products: bryostatins in preclinical and clinical studies.
    Kollár P; Rajchard J; Balounová Z; Pazourek J
    Pharm Biol; 2014 Feb; 52(2):237-42. PubMed ID: 24033119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiogenesis and angiogenesis inhibitors in cancer.
    Giavazzi R; Taraboletti G
    Forum (Genova); 1999; 9(3):261-72. PubMed ID: 10504172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Marine pharmacology in 2000: antitumor and cytotoxic compounds.
    Mayer AM; Gustafson KR
    Int J Cancer; 2003 Jun; 105(3):291-9. PubMed ID: 12704660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural products as angiogenesis modulators.
    El Sayed KA
    Mini Rev Med Chem; 2005 Nov; 5(11):971-93. PubMed ID: 16307528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
    Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
    Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Marine natural product drug discovery: Leads for treatment of inflammation, cancer, infections, and neurological disorders.
    Villa FA; Gerwick L
    Immunopharmacol Immunotoxicol; 2010 Jun; 32(2):228-37. PubMed ID: 20441539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotherapeutics from natural products: from bench to clinics?
    Bernas G
    Clin Hemorheol Microcirc; 2003; 29(3-4):199-203. PubMed ID: 14724342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is copper chelation an effective anti-angiogenic strategy for cancer treatment?
    Antoniades V; Sioga A; Dietrich EM; Meditskou S; Ekonomou L; Antoniades K
    Med Hypotheses; 2013 Dec; 81(6):1159-63. PubMed ID: 24210000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?
    Bozza C; Fontanella C; Buoro V; Mansutti M; Aprile G
    Expert Rev Clin Pharmacol; 2015 Mar; 8(2):251-65. PubMed ID: 25597501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular galectins: regulators of tumor progression and targets for cancer therapy.
    Thijssen VL; Rabinovich GA; Griffioen AW
    Cytokine Growth Factor Rev; 2013 Dec; 24(6):547-58. PubMed ID: 23942184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and development of polymer conjugates as anti-angiogenic agents.
    Segal E; Satchi-Fainaro R
    Adv Drug Deliv Rev; 2009 Nov; 61(13):1159-76. PubMed ID: 19699248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Marine Compounds and Cancer: Updates 2020.
    Dyshlovoy SA; Honecker F
    Mar Drugs; 2020 Dec; 18(12):. PubMed ID: 33333876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
    van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT
    Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors.
    Crawford Y; Ferrara N
    Methods Enzymol; 2008; 445():125-39. PubMed ID: 19022058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.